We were fascinated by the Review article by Jeremy M. Kinder et al. (Immunological implications of pregnancy-induced microchimerism. Nat. Rev. Immunol. 17, 483–494 (2017))1, which discusses the bidirectional exchange of maternal and fetal cells during pregnancy and the potential benefits and harmful effects of this microchimerism. These cells may persist for a long time, and circulating maternal cells have been detected for up to 62 years in the offspring, resulting in the so-called maternal microchimerism (MMc). It has been estimated that, due to MMc, up to 1 in 5,000 peripheral blood mononuclear cells are of maternal origin2.
In addition to pregnancy-related MMc, compelling evidence points to the existence of a postnatal MMc present in the infant, which is related to breastfeeding. Experiments in rodents and non-human primates3,4, and limited human-based observations, support the idea that cells from breast milk may traffic from the mother to the infant's tissues through the gut mucosae. This phenomenon is likely to occur mainly during the early stages of lactation, at a time when breast milk cells are abundant and the infant's gut permeability is highest. The precise nature of the maternal cells present in breast milk that are involved in microchimerism is presently unknown but may include stem cells and progenitor cells as well as mature immune cells.
Colostrum (the form of milk produced in the first 4 days of lactation) contains high numbers of maternal cells of various types including epithelial cells, T and B lymphocytes, natural killer (NK) cells, dendritic cells, macrophages and others. In the weeks after birth, the immune cell concentration of breast milk decreases rapidly5. Breast milk lymphocytes consist mainly of an extra-lymphoid memory cell population6. Most CD4+ and CD8+ T cells are effector memory cells7,8. Up to 6% of breast milk cells are progenitor or stem cells of haemopoietic, mesenchymal and neuroepithelial lineages9,10. Some of these cells express markers that suggest a mesenchymal stem cell phenotype (CD90, CD44, CD271 and CD146), some express markers of embryonic stem cells (TRA-1-60, octamer-binding protein 4 (OCT4), NANOG and SOX2) and some express markers of luminal mammary epithelial cells (cytokeratin 18)11. Given their potential, breast milk stem cells are good candidates for long-term MMc in the infant intestinal tissues. Indeed, it is likely that infants may become tolerant to stem cells of maternal origin as these cells do not express MHC antigens.
A recent study from the group of Sing Sing Way established the cross-generational reproductive benefit conferred by maternal microchimerism, which involved the persistence of non-inherited maternal antigen-specific regulatory T cells of fetal origin in the genital tract of female offspring12. In this study, there was a direct quantitative relationship between MMc and cross-generational reproductive fitness. We can therefore hypothesize that, if tolerance and reproductive fitness (and potentially other consequences such as tissue healing and immune modulation) are quantitative functions of pregnancy-related MMc, breastfeeding-related MMc may increase these beneficial functions in the child in an additive or synergistic fashion.
The transfer of viable maternal immune and stem cells from breast milk to an infant may contribute to optimizing neonatal and infant immune system maturation, tissue repair and immune tolerance and thereby complement pregnancy-related MMc.
There is a Reply associated with this Correspondence by Jeremy M. Kinder, Ina A. Stelzer, Petra C. Arck and Sing Sing Way, Nat. Rev. Immunol. http://dx.doi.org/10.1038/nri.2017.117 (2017).